The role of the new Ca2+ antagonist, CV159, in hepatic I/R injury-the evaluation of hepatic organ reducing activity using in vivo and ex vivo EPR.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples